Skip to main content
ZJAMP Group Co., Ltd. logo

ZJAMP Group Co., Ltd. — Investor Relations & Filings

Ticker · 002758 ISIN · CNE100002029 LEI · 3003009OKT32LB5C0T64 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,563 across all filing types
Latest filing 2019-04-19 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002758

About ZJAMP Group Co., Ltd.

https://www.znjtgf.com

ZJAMP Group Co., Ltd. specializes in the comprehensive distribution and supply chain management of agricultural production materials. The company’s core operations encompass the procurement, storage, and sale of essential inputs, including chemical fertilizers such as urea, potash, and compound fertilizers, as well as pesticides, seeds, and agricultural machinery. Beyond product distribution, the organization provides integrated technical services, modern logistics solutions, and agricultural consultancy to enhance crop yields and farming efficiency. By leveraging an extensive network of distribution centers and service stations, the group facilitates the stable supply of high-quality agricultural resources. Its business model focuses on bridging the gap between manufacturers and end-users through efficient resource allocation and value-added services.

Recent filings

Filing Released Lang Actions
董事会关于本次交易符合《关于规范上市公司重大资产重组若干问题的规定》第四条规定的说明
Board/Management Information Classification · 95% confidence The document is a statement from the board of directors of Zhejiang Huatong Pharmaceutical Co., Ltd. regarding the compliance of a major asset restructuring transaction with regulatory provisions. It discusses the purchase of 100% shares of a company, the legal and regulatory compliance of the transaction, and the benefits to the company. The document is a formal explanation and analysis by the board about the transaction's compliance with specific regulatory rules on major asset restructurings. It is not a full annual or interim report, audit report, or earnings release. It is not a voting result or a proxy statement. It is a detailed board-level explanation related to a significant transaction, which fits the category of Board/Management Information (MANG). The document length is short (1243 characters), and it is not an announcement of a report publication but a substantive explanation by the board. Therefore, the appropriate classification is MANG.
2019-04-19 Chinese
第三届董事会第二十会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement of resolutions passed by the board of directors of Zhejiang Huatong Pharmaceutical Co., Ltd. regarding a major asset restructuring involving the issuance of shares to purchase assets and related party transactions. It includes detailed descriptions of the transaction, voting results, legal compliance, and procedural matters. The document is not a full annual or interim financial report, nor is it a simple announcement of a report publication. It is not a call transcript, earnings release, or remuneration report. The content focuses on board meeting resolutions related to a significant capital transaction and asset acquisition, which fits the category of Capital/Financing Update (CAP). The document length (9110 characters) and detailed content confirm it is a substantive announcement rather than a brief notice or certification. Therefore, the appropriate classification is CAP with high confidence.
2019-04-19 Chinese
关于发行股份购买资产暨关联交易预案披露及公司股票复牌的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (959 characters) from Zhejiang Huatong Pharmaceutical Co., Ltd. It discusses the company's plan to issue shares to purchase assets and related party transactions, as well as the resumption of trading of its stock and convertible bonds. It mentions the approval of a board meeting resolution and the need for further approvals including shareholder meeting and regulatory approval. The document does not contain detailed financial data or full report content but rather informs about the progress and next steps of a capital/asset transaction and stock resumption. It fits the category of Capital/Financing Update (CAP) because it relates to issuance of shares for asset purchase and stock trading resumption, which are financing activities. It is not a full report, earnings release, or regulatory filing. Therefore, the best classification is CAP with high confidence.
2019-04-19 Chinese
第三届监事会第十六次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Zhejiang Huatong Pharmaceutical Co., Ltd. It details the meeting held on April 18, 2019, including approvals of the 2018 Supervisory Board work report, 2018 financial statements, profit distribution plan, annual report, fundraising usage report, internal control self-assessment report, appointment of the 2019 audit firm, project delays, and accounting policy changes. The document references the 2018 annual report and other reports but does not contain the full annual report or detailed financial statements itself. It is a formal announcement of meeting resolutions and approvals, not the full annual report or audit report. The document length is 3283 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best as a Regulatory Filing (RNS) since it is a formal regulatory announcement of supervisory board meeting resolutions and related approvals, not the full annual report or audit report itself.
2019-04-19 Chinese
独立董事候选人声明（谭国春）
Regulatory Filings Classification · 95% confidence The document is a formal declaration by an independent director candidate of Zhejiang Huatong Pharmaceutical Co., Ltd. It contains detailed statements about the candidate's qualifications, compliance with regulatory requirements, and independence criteria as per various Chinese regulatory bodies and stock exchange rules. There is no financial data, no discussion of company performance, no voting results, no management changes, and no mention of any report publication. The document is a regulatory compliance statement related to board membership qualifications. This type of document fits best under Regulatory Filings (RNS) as it is a formal regulatory disclosure that does not fit other specific categories.
2019-04-19 Chinese
关于召开2018年度股东大会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2018 Annual General Meeting (AGM) of Zhejiang Huatong Pharmaceutical Co., Ltd. It includes information about the meeting date, location, voting procedures (both in-person and online), agenda items to be discussed and voted on, and instructions for shareholders on how to participate and vote. The document does not contain the actual annual report or financial statements but rather the notification and procedural details for the AGM. This matches the definition of AGM Information (AGM-R), which covers presentations and materials shared during the AGM or notices about the AGM itself. The document length is about 5115 characters, which is consistent with a detailed AGM notice rather than a full annual report or other filings. Therefore, the correct classification is AGM Information (AGM-R).
2019-04-19 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.